Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

PURPOSE: Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Gul, Anita, Stewart, Tyler F., Mantia, Charlene M., Shah, Neil J., Gatof, Emily Stern, Long, Ying, Allman, Kimberly D., Ornstein, Moshe C., Hammers, Hans J., McDermott, David F., Atkins, Michael B., Hurwitz, Michael, Rini, Brian I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7499610/
https://ncbi.nlm.nih.gov/pubmed/32491962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03315
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados